Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3433)	7/14/1999 2:45:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Don, Yes I saw those. There was also mention at the annual meeting of encouraging anecdotal reports - both people responding to Xopenex that didn't respond to albuterol, and people tolerating Xopenex that couldn't tolerate albuterol. That said, I just want people to be realistic about how quickly an improved drug like Xopenex gets adopted. It's not like a new drug that has an immediate unserved population eagerly waiting for it. It's a slow, educative process - a doctor might try it for a few patients, and then, if impressed by the results, gradually switch existing/new patients over to it. These days, word-of-internet is increasingly important, but here again remember we are still only in the nebulizer format, where what the doctors think is more important than what the patients think. Peter